Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...

Research analysts at HC Wainwright issued their FY2025 EPS estimates for Grace Therapeutics in a research note issued to investors on Tuesday, February 18th. HC Wainwright analyst O. Livnat ...

H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...

H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Biotricity (BTCY – Research Report) today. The company’s shares closed yesterday ...

Looking at options history for Cleanspark CLSK we detected 29 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief ...

Delving into the details, we found 70% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we ...

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...

Despite the regulatory setback, analysts appear optimistic, noting that Harmony’s long-term prospects remain bright given the ...

Discover Balchem's record-breaking Q4 2024 performance with $240M in sales and innovation-driven growth in nutrition segments.